Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | UBE2M | P61081 | 5/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29081450 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TP53UBE2MDCUN1D1PDE10A | |
| SCHEMBL24366673 | 1.00 | ALDH1A1 (0.39) | ALDH1A1TP53UBE2MDCUN1D1PDE10A | |
| SCHEMBL24233756 | 0.86 | NPC1 (0.37) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL24363794 | 0.86 | NPC1 (0.37) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL25324407 | 0.84 | NPC1 (0.34) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL30551016 | 0.84 | NPC1 (0.34) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL24233907 | 0.83 | NPC1 (0.37) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL32689340 | 0.83 | NPC1 (0.36) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL24365738 | 0.83 | NPC1 (0.36) | ALDH1A1TP53UBE2MDCUN1D1LMNA | |
| SCHEMBL29081416 | 0.83 | NPC1 (0.36) | ALDH1A1TP53UBE2MDCUN1D1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-4188920-A1 | PIPERIDIN-1-YL-N-PYRYDINE-3-YL-2-OXOACETAMIDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MTA-ACCUMULATING CANCERS | Tango Therapeutics, Inc. (US) | 2023-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | ALDH1A1 100/4885TP53 3467/4885UBE2M 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.